<DOC>
	<DOC>NCT00464399</DOC>
	<brief_summary>To evaluate the safety and tolerability of early switch to everolimus from cyclosporine A in de novo renal transplant recipients by assessing rejection rate everolimus trough levels, other safety laboratory variables and adverse events.</brief_summary>
	<brief_title>Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Male or female aged above 18 years. Patients having received their first or second single renal transplant from deceased or living donor Patient willing and capable of giving written informed consent for study participation Patients treated with as induction therapy at the time of transplantation Patients maintained on a triple immunosuppressive regime consisting of cyclosporine (C0 h between 100250 ng/ml or a C2 h between 9001100 ng/ml), Enteric coated mycophenolate sodium (ECMPS), minimum dose 1080 mg and corticosteroids, minimum dose 10 mg Patients without any biopsy proven acute rejection episode or treatment for any acute rejection since the transplant Females capable of becoming pregnant must have a negative pregnancy test prior to the switch to everolimus and are required to practice a medically approved method of birth control for the duration of the study and a period of 8 weeks following discontinuation of study medication, even where there has been a history of infertility. Recipient of multiorgan transplants, and or previously transplanted with any other organ different from a kidney transplant Patients with antibodies towards the donor kidney above 30% Patients receiving a renal transplant from HLAidentical sibling Presence of hyper sensitivity to drugs similar to everolimus ( e.g. macrolides) Patient with past (within the last two years) or present malignancy other than excised basal cell or squamous cell carcinoma of the skin Patients who are recipients of AB0 incompatible transplants Patients with unsuitable laboratory values Patients with ongoing wound healing problems or other severe surgical complication in the opinion of the investigator Patient with a current severe major local or systemic infection Patients requiring dialysis and/or having a calculated glomerular filtration rate (CockcroftGault) &lt; 20 ml/min Presence of intractable immunosuppressant complications or side effects (e.g., severe gastrointestinal adverse events) at the time of the switch Patients who are HIV positive or Hepatitis B surface antigen positive or Hepatitis C virus positive. Recipients of organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C are excluded. Evidence of severe liver disease Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>De novo renal transplantation</keyword>
	<keyword>CNI-free protocol</keyword>
	<keyword>adults</keyword>
	<keyword>everolimus</keyword>
	<keyword>rejections</keyword>
</DOC>